A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

Back to Search
Print
Bookmark Trial

NCT00219622

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, 85006, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Obstructive Pulmonary Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Moderate-severe COPD (GOLD 2003 definition)

- Smoking history of at least 10 pack-years

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any significant co-morbid disease, particularly cardiovascular


- Use of any maintenance therapy except short acting bronchodilators

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Chronic Obstructive Pulmonary DiseaseMultiple Dose Healthy Volunteer Safety Pharmacokinetics Study NCT00864786
  1. Bruxelles,
Male
18 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseA Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD). NCT00559910
  1. La Plata, Buenos Aires
  2. Buenos Aires, Capital Federal
  3. Buenos Aires, Capital Federal
  4. Ciudad Autonoma de Buenos Aires (CABA), Capital Federal
  5. Rosario, Santa Fe
  6. Camperdown, New South Wales
  7. Daw Park, South Australia
  8. Nedlands, Western Australia
  9. Vancouver, British Columbia
  10. Winnipeg, Manitoba
  11. Hamilton, Ontario
  12. Kingston, Ontario
  13. Sainte-Foy, Quebec
  14. Providencia, Santiago, RM
  15. Valparaiso, V Región
  16. Talca,
  17. Cvikov,
  18. Kutna Hora,
  19. Liberec,
  20. Praha 5,
  21. Strakonice,
  22. Tabor,
  23. Lille,
  24. Marseille,
  25. Montpellier,
  26. Perpignan,
  27. Athens,
  28. Heraklion,
  29. Larissa,
  30. Budapest,
  31. Budapest,
  32. Deszk,
  33. Pecs,
  34. Szombathely,
  35. Anyang,
  36. Seoul,
  37. Seoul,
  38. Almere,
  39. Zutphen,
  40. Yaroslavl,
  41. Yaroslavl,
  42. Durban, Kwa-Zulu Natal
  43. Bloemfontein,
  44. Durban,
  45. Edinburgh,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseA Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers NCT01364519
  1. Manchester, Greater Manchester
  2. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseasePhase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD NCT00263874
  1. La Plata, Buenos Aires
  2. Vicente Lopez, Buenos Aires
  3. Rosario, Santa Fé
  4. Buenos Aires,
  5. Buenos Aires,
  6. Camperdown, New South Wales
  7. Clayton, Victoria
  8. Nedlands, Western Australia
  9. Calgary, Alberta
  10. Red Deer, Alberta
  11. Hamilton, Ontario
  12. Kingston, Ontario
  13. Santiago, RM
  14. Providencia, Santiago
  15. Valparaíso,
  16. Zagreb,
  17. Olomouc,
  18. Ostrava-Poruba,
  19. Praha 5,
  20. Tabor,
  21. Debrecen,
  22. Torokbalint,
  23. Veszprem,
  24. Singapore,
  25. Singapore,
  26. Madrid,
  27. Madrid,
  28. Manchester,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
Official Title  ICMJE Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six Week Study Of The Efficacy And Safety Of Tofimilast Dry Powder For Inhalation In Adults Diagnosed With Chronic Obstructive Pulmonary Disease
Brief Summary This an initial proof of concept, phase to study to assess the safety and efficacy of tofimilast for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Pulmonary Disease, Chronic Obstructive
Intervention  ICMJE Drug: tofimilast
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 14, 2005)		300
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 2005
Actual Primary Completion Date July 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Moderate-severe COPD (GOLD 2003 definition)
  • Smoking history of at least 10 pack-years

Exclusion Criteria:

  • Any significant co-morbid disease, particularly cardiovascular
  • Use of any maintenance therapy except short acting bronchodilators
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Brazil,   Chile,   Costa Rica,   Mexico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00219622
Other Study ID Numbers  ICMJE A2641022
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP